Research output per year
Research output per year
Search results
-
2017
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747)
Andronis, L., Goranitis, I., Pirrie, S., Pope, A., Barton, D., Collins, S., Daunton, A., McLaren, D., O'Sullivan, J. M., Parker, C., Porfiri, E., Staffurth, J., Stanley, A., Wylie, J., Beesley, S., Birtle, A., Brown, J. E., Chakraborti, P., Hussain, S. A., Russell, J. M., & 2 others, Apr 2017, In: BJU international. 119, 4, p. 522-529 8 p.Research output: Contribution to journal › Article › peer-review
Open AccessFile11 Citations (Scopus)281 Downloads (Pure) -
2016
Clinical outcomes and survival following treatment of Metastatic Castrate-Refractory Prostate Cancer With docetaxel alone or with strontium-89, zoledronic acid, or both: The TRAPEZE Randomized Clinical Trial
James, N. D., Pirrie, S. J., Pope, A. M., Barton, D., Andronis, L., Goranitis, I., Collins, S., Daunton, A., McLaren, D., O'Sullivan, J., Parker, C., Porfiri, E., Staffurth, J., Stanley, A., Wylie, J., Beesley, S., Birtle, A., Brown, J., Chakraborti, P., Hussain, S., & 2 others, Apr 2016, In: JAMA Oncology. 2, 4, p. 493-499 7 p.Research output: Contribution to journal › Article › peer-review
Open Access50 Citations (Scopus) -
2015
Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer. (ISRCTN 12808747) TRAPEZE
James, N., Andronis, L., Goranitis, I., Pope, A., Pirrie, S., Barton, D., Daunton, A., McLaren, D. & Billingham, L., Jun 2015.Research output: Contribution to conference (unpublished) › Poster